Most Read Articles
21 Jun 2017
Young children may learn deception for their benefit within 10 days, a new study shows. Moreover, the children’s capacities for hiding truthful information and for representing mental life determine the rate at which they learn deception.
05 Jul 2017
Intrauterine exposure to artificially sweetened beverage (ASB) contributes to an increase in birth size and in the risk of overweight or obesity at 7 years of age, a study has found.
19 Jul 2017
Mothers who have high consumption of refined grains during pregnancy are likely to have offspring with higher body mass index z score (BMIZ) and greater risk of overweight or obesity at age 7 years, a recent study has found.
16 Jul 2017
Feeding with donor breast milk (DBM) may compromise early in-hospital weight gain and potentially lead to early cognitive delays in preterm infants as compared with mother’s own milk (MOM) or preterm formula (PF), a study suggests.

Original New Drug Application Approvals by US FDA (16 - 31 July 2017)

31 Jul 2017
New drug applications approved by US FDA as of 16 - 31 July 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

NERLYNX
  • Active Ingredient(s): NERATINIB MALEATE
  • Strength: 40MG
  • Dosage Form: Oral Tablet
  • Company: Puma Biotech Inc
  • Approval Date: July 17, 2017
  • Chemical Type: Type 1 - New Molecular Entity
  • Indication(s): Indicated for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy
  • Approved Label: 07/17/2017 (PDF)

VOSEVI
  • Active Ingredient(s): SOFOSBUVIR;VELPATASVIR;VOXILAPREVIR
  • Strength: 400MG;100MG;100MG
  • Dosage Form: Oral Tablet
  • Company: Gilead Sciences Inc
  • Approval Date: July 18, 2017
  • Chemical Type: Type 1 - New Molecular Entity and Type 4 - New Combination
  • Indication(s): Indicated for the treatment of adult patients with chronic HCV infection without cirrhosis or with compensated cirrhosis (Child-Pugh A) who have (1, 2.2, 14):
    • genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen containing an NS5A inhibitor
    • genotype 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor: Additional benefit of VOSEVI over sofosbuvir/velpatasvir was not shown in adults with genotype 1b, 2, 4, 5, or 6 infection previously treated with sofosbuvir without an NS5A inhibitor
  • Approved Label: 07/18/2017 (PDF)

LUSDUNA
  • Active Ingredient(s): INSULIN GLARGINE
  • Strength: 100UNITS/ML
  • Dosage Form: Injectable; Injection
  • Company: Merck Sharp Dohme
  • Approval Date: July 19, 2017
  • Chemical Type: Type 5 - New Formulation or New Manufacturer
  • Indication(s): Indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus
  • Approved Label: Not available

BENLYSTA
  • Active Ingredient(s): BELIMUMAB
  • Strength: 200MG/ML
  • Dosage Form: Injectable;Injection
  • Company: Glaxosmithkline LLC
  • Approval Date: July 20, 2017
  • Chemical Type: Not available
  • Indication(s): Indicated for the treatment of adult patients with active, autoantibody-positive, systemiclupus erythematosus who are receiving standard therapy
  • Approved Label: 07/20/2017 (PDF)

NITYR
  • Active Ingredient(s): NITISINONE
  • Strength: 2MG, 5MG, 10MG
  • Dosage Form: Oral Tablet
  • Company: Cycle Pharms LTD
  • Approval Date: July 26, 2017
  • Chemical Type: Type 5 - New Formulation or New Manufacturer
  • Indication(s): Indicated for the treatment of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine
  • Approved Label: 07/26/2017 (PDF)

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
21 Jun 2017
Young children may learn deception for their benefit within 10 days, a new study shows. Moreover, the children’s capacities for hiding truthful information and for representing mental life determine the rate at which they learn deception.
05 Jul 2017
Intrauterine exposure to artificially sweetened beverage (ASB) contributes to an increase in birth size and in the risk of overweight or obesity at 7 years of age, a study has found.
19 Jul 2017
Mothers who have high consumption of refined grains during pregnancy are likely to have offspring with higher body mass index z score (BMIZ) and greater risk of overweight or obesity at age 7 years, a recent study has found.
16 Jul 2017
Feeding with donor breast milk (DBM) may compromise early in-hospital weight gain and potentially lead to early cognitive delays in preterm infants as compared with mother’s own milk (MOM) or preterm formula (PF), a study suggests.